falsefalse

EHA 2024: Updates in the Treatment of CLL    - Episode 20

Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

, , , ,

Key opinion leaders provide concise insights on the potential of bispecific antibodies as emerging novel therapeutic agents for relapsed/refractory chronic lymphocytic leukemia.

Video Player is loading.
Current Time 0:00
Duration 4:39
Loaded: 0%
Stream Type LIVE
Remaining Time 4:39
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Video content above is prompted by the following:

  • Briefly share perspective/insights on emerging novel agents in R/R CLL: Bispecific antibodies
x